cis‐regulatory control of Mesp1 expression by YY1 and SP1 during mouse embryogenesis

Abstract

Background: Mesp1 is critical for early cardiomyocyte differentiation and heart development. We previously observed downregulation of Mesp1 expression in YY1-ablated mouse embryonic hearts. However, how Mesp1 expression is mediated by YY1 is not well understood. Results: We excised YY1 in the murine embryos using Sox2-cre and found that Mesp1 was downregulated in the embryonic day (E) 7.5 mutant embryos. Also, YY1 activated the 6 kb Mesp1 regulatory element fused to a luciferase reporter. We identified two putative YY1 binding sites in the proximal promoter region of Mesp1 gene, and found that mutation of these sites significantly reduced YY1-induced activation of the Mesp1 promoter. We also uncovered one cognitive site for SP1, one of the earliest binding partners of YY1 identified. Mutation of this SP1 site repressed SP1-induced activation of the Mesp1 promoter. Moreover, YY1 and SP1 synergistically activated the Mesp1 promoter. Consistently, while Lacz expression driven by the wild-type 6 kb regulatory element of Mesp1 gene was robust in E7.5 mouse embryos, the mutation of these binding sites in the context of this 6 kb sequence substantially reduced the LacZ expression during embryogenesis. Conclusions: YY1 and SP1 independently and cooperatively govern the Mesp1 expression during embryogenesis. Developmental Dynamics 245:379-387, 2016. V C 2015 Wiley Periodicals, Inc.

Transposable elements drive widespread expression of oncogenes in human cancers

“…In both H1299 and H838, mutating SP1, SP4, and YY1 sites significantly diminished relative luciferase expression, which is consistent with previous findings that SP transcription factors cooperate with YY1 to drive strong promoter expression (Fig. 2d) 38 . Furthermore, these results were recapitulated in the K562 leukemia cell line (Supplementary Fig.…”

The CSRP2BP histone acetyltransferase drives smooth muscle gene expression

“…In the present study, we chose to use suboptimal dosage of these transcription factors to reduce overall reporter activity, which allowed us to test CSRP2BP as a transactivator. This is a standard practice for identification of important co-factors (36,37). …”

Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K

“…In the central nervous system, dysbindin enacts its chief functions of facilitating neurite outgrowth and regulating synaptic activity (Liao and Chen, 2004;Ma et al, 2011). Moreover, two following binding sites for transcription factors were identified in the promotor region of dysbindin: nuclear factor-1 (NF-1) and specificity protein-1 (SP-1), both of which may regulate cell growth and embryogenesis (Liao and Chen, 2004;Plachez et al, 2008;Zhao et al, 2013;Beketaev et al, 2016). Transcription factor E2F1, which regulates cell growth and proliferation, can bind to the dysbindin promoter and cause a 10-fold increase in dysbindin expression (Iwanaga et al, 2006).…”